05/28/2026
Estrogen and Brain Health—What the Research Says:
The relationship between estrogen and cognitive function is one of the most compelling areas in women's health research.
Estrogen receptors are found throughout the brain, including in regions responsible for memory and executive function. During perimenopause and menopause, declining estrogen levels correlate with increased reports of brain fog, word-finding difficulties, and memory lapses.
The 'critical window' hypothesis suggests that hormone therapy initiated within 10 years of menopause onset may be protective against cognitive decline. Studies from the Cache County Study and WHIMS-Y trial have added nuance to this conversation.
The Cache County Study on Memory in Aging is a long-term, population-based observational study of older adults in Utah. It revealed that women who initiated hormone therapy within five years of menopause had up to a 37% reduced risk of Alzheimer’s disease, especially when used for a decade or longer. However, the study found no cognitive protection for women who began hormone treatments five or more years after menopause.
The WHIMS-Y (Women's Health Initiative Memory Study of Younger Women) was a clinical trial designed to specifically evaluate the cognitive effects of hormone therapy on postmenopausal women aged 50 to 55. By examining the younger demographic, the WHIMS-Y trial contributed to clinical consensus that hormone therapy does not hold a high risk for cognitive decline and may offer cognitive stability when prescribed closer to the onset of menopause.
Importantly, the form and route of hormone delivery matter. Transdermal estradiol does not carry the same thromboembolic risk as oral conjugated equine estrogen—a distinction that significantly changes the risk-benefit calculation.
This is why individualized hormone therapy, guided by labs and symptoms, matters.
